EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system (CNS) diseases, has announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (?7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease (AD). The program is being conducted under a Special Protocol Assessment agreement with the FDA.
More...
More...